CETRAXAL (Ciprofloxacin 0,2%) Otic solution, an effective antibiotic for the treatment of external otitis in a sterile, single-dispensing container (SDC) format. CETRAXAL Otic combines the advantages of a proven, effective antibiotic with a simple, accurate and sterile form of administration. The idea behind the product is to reduce unnecessary ingredients thus avoiding unexpected adverse reactions, especially problematic in the pediatric population.

CETRAXAL PLUS (Ciprofloxacin 0,3% + Fluocinolone 0,25%) Otic solution, an effective antibiotic for the treatment of external otitis, combined with a safe corticoide in order to reduce inflammation.

CETRAXAL (Ciprofloxacin 0,2%) Otic solution: Decentralised Procedure started in June 2008 in Netherlands. Concerned Member States: Italy, Greece, France, UK,Germany.

CETRAXAL PLUS (Ciprofloxacin 0,3% + Fluocinolone 0,25%) Otic solution: Mutual Recognition Procedure with Spain as Reference Member State, product already approved an launched in Spain will start in 3rd quater of 2008. Concerned Member States: France, UK,Germany, Netherlands.

Additional Countries will be added on request.

Licensing Agreement with exclusive supply by SALVAT.